State Street’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

State Street’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-816	Closed	-$9.62K	–	4777
2023 Q1	$9.62K	Hold	816	–	–	﹤0.01%	4745
2022 Q4	$11.8K	Hold	816	–	–	﹤0.01%	4791
2022 Q3	$41K	Hold	816	–	–	﹤0.01%	4701
2022 Q2	$70K	Sell	816 -2,824	-78%	-$242K	﹤0.01%	4652
2022 Q1	$549K	Buy	3,640 +99	+3%	+$22.8K	﹤0.01%	4010
2021 Q4	$1.06M	Buy	3,541 +61	+2%	+$23.4K	﹤0.01%	3802
2021 Q3	$1.36M	Buy	3,480 +1,113	+47%	+$474K	﹤0.01%	3726
2021 Q2	$999K	Buy	+2,367	New	+$1.02M	﹤0.01%	3664

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

State Street's FNCH Position: Q2 2023 in Review

State Street sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 816 shares — an estimated $9.62K sold.

State Street first reported a position in FNCH in Q2 2021 and held it in 8 quarters. The position peaked at $1.36M in Q3 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

State Street reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 816 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $9.62K.
State Street first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
State Street's Finch Therapeutics Group, Inc. Common Stock position peaked at $1.36M in Q3 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.